Buy Rating Affirmed for Biomea Fusion with Promising BMF-219 Clinical and Regulatory Developments
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...
Piper Sandler Remains a Buy on Biomea Fusion (BMEA)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a ...
US FDA lifts clinical hold on Biomea’s diabetes trials after safety review
The drug BMF-219 works by increasing, preserving and reactivating patients’ own healthy insulin-producing cells. Read more at ...
The Globe and Mail18s
Dow Jones Climbs to New Record Highs, While the Nasdaq Slides
Biomea Fusion (BMEA) is up more than +20% after Truist Securities upgraded the stock to buy from hold with a price target of $54. Establishment Labs Holdings (ESTA) is up more than +14% after it ...
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...